New Benzodihydrofuran Derivatives Alter the Amyloid β Peptide Aggregation: Strategies To Develop New Anti-Alzheimer Drugs.
暂无分享,去创建一个
J. Fuentealba | Claudio A. Jiménez | C. F. Burgos | Alexander F de la Torre | F. Sáez-Orellana | C. Castillo | Jhon J. López | Yaima Sánchez | Francisco Sáez-Orellana
[1] Ting Deng,et al. The cellular model for Alzheimer's disease research: PC12 cells , 2023, Frontiers in Molecular Neuroscience.
[2] G. Tang,et al. New benzofuran neolignans with neuroprotective activity from Phyllanthodendron breynioides. , 2022, Natural product research.
[3] S. Sadigh-Eteghad,et al. Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews , 2022, European Journal of Clinical Pharmacology.
[4] M. Chorilli,et al. Insights for Alzheimer's disease pharmacotherapy and current clinical trials , 2022, Neurochemistry International.
[5] Diogo Santos-Martins,et al. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings , 2021, J. Chem. Inf. Model..
[6] M. Pinto,et al. Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness , 2021, Molecules.
[7] Yang Ouyang,et al. Chalcone Derivatives: Role in Anticancer Therapy , 2021, Biomolecules.
[8] W. Suo,et al. Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease. , 2021, Bioorganic chemistry.
[9] B. Salehi,et al. Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence , 2021, Frontiers in Pharmacology.
[10] P. Faller,et al. Reproducibility Problems of Amyloid-β Self-Assembly and How to Deal With Them , 2021, Frontiers in Chemistry.
[11] M. Arbitrio,et al. The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease , 2021, Journal of central nervous system disease.
[12] Y. Kim,et al. Associations between metabolic syndrome and type of dementia: analysis based on the National Health Insurance Service database of Gangwon province in South Korea , 2020, Diabetology & Metabolic Syndrome.
[13] Jevgenij A. Raskatov,et al. Assessing Reproducibility in Amyloid β Research: Impact of Aβ Sources on Experimental Outcomes , 2020, Chembiochem : a European journal of chemical biology.
[14] E. Barg,et al. PC12 Cell Line: Cell Types, Coating of Culture Vessels, Differentiation and Other Culture Conditions , 2020, Cells.
[15] M. Xiong,et al. Shared Causal Paths underlying Alzheimer’s dementia and Type 2 Diabetes , 2020, Scientific Reports.
[16] D. Broszczak,et al. Oxidative stress in alzheimer's disease: A review on emergent natural polyphenolic therapeutics. , 2020, Complementary therapies in medicine.
[17] J. Fuentealba,et al. Exploring the Multi–Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer’s Disease , 2020, Frontiers in Pharmacology.
[18] G. Smith,et al. The causes and consequences of Alzheimer’s disease: phenome-wide evidence from Mendelian randomization , 2019, Nature Communications.
[19] H. Mori,et al. Sustained Neurotrophin Release from Protein Nanoparticles Mediated by Matrix Metalloproteinases Induces the Alignment and Differentiation of Nerve Cells , 2019, Biomolecules.
[20] F. Belluti,et al. Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. , 2019, European journal of medicinal chemistry.
[21] D. Dickson,et al. The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.
[22] C. Dobson,et al. Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates , 2019, Science Advances.
[23] Francesca Seghetti,et al. The Keap1/Nrf2-ARE Pathway as a Pharmacological Target for Chalcones , 2018, Molecules.
[24] J. Marco-Contelles,et al. Alzheimer's Disease, the "One-Molecule, One-Target" Paradigm, and the Multitarget Directed Ligand Approach. , 2018, ACS chemical neuroscience.
[25] Xingmei Duan,et al. Shikonin Protects PC12 Cells Against β-amyloid Peptide-Induced Cell Injury Through Antioxidant and Antiapoptotic Activities , 2018, Scientific Reports.
[26] Eugene N. Muratov,et al. Chalcone Derivatives: Promising Starting Points for Drug Design , 2017, Molecules.
[27] C. Xing,et al. Chalcone: A Privileged Structure in Medicinal Chemistry. , 2017, Chemical reviews.
[28] L. Fershtat,et al. Molecular Hybridization Tools in the Development of Furoxan‐Based NO‐Donor Prodrugs , 2017, ChemMedChem.
[29] Wenhua Zheng,et al. Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway , 2017, Redox biology.
[30] Ying Peng,et al. Bioactive Benzofuran Derivatives from Cortex Mori Radicis, and Their Neuroprotective and Analgesic Activities Mediated by mGluR1 , 2017, Molecules.
[31] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[32] W. Geldenhuys,et al. Pharmacotherapy of Alzheimer’s disease: current and future trends , 2015, Expert review of neurotherapeutics.
[33] M. Kumar,et al. Benzofuran–Chalcone Hybrids as Potential Multifunctional Agents against Alzheimer’s Disease: Synthesis and in vivo Studies with Transgenic Caenorhabditis elegans , 2014, ChemMedChem.
[34] J. Wiltfang,et al. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. , 2014, ACS chemical neuroscience.
[35] A. Joerger,et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.
[36] V. Andrisano,et al. 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. , 2012, European journal of medicinal chemistry.
[37] Srikar Appalaraju,et al. Microwave-Assisted Synthesis and Pharmacological Activity of Pyrazolyl Benzofuran Deravatives , 2012 .
[38] Weiliang Zhu,et al. Halogen bonding for rational drug design and new drug discovery , 2012, Expert opinion on drug discovery.
[39] R. Ferrante,et al. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. , 2012, Bioorganic & medicinal chemistry.
[40] Suengmok Cho,et al. Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. , 2011, Biochemical and biophysical research communications.
[41] C. G. Mohan,et al. Antiobesity and lipid lowering effects of Glycyrrhiza chalcones: experimental and computational studies. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[42] Marcelo Zaldini Hernandes,et al. Halogen atoms in the modern medicinal chemistry: hints for the drug design. , 2010, Current drug targets.
[43] Shinji Ohta,et al. C-geranylated chalcones from the stems of Angelica keiskei with superoxide-scavenging activity. , 2008, Journal of natural products.
[44] V. Andrisano,et al. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. , 2008, Journal of medicinal chemistry.
[45] E. Barreiro,et al. Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.
[46] H. Kung,et al. Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. , 2006, Journal of medicinal chemistry.
[47] J. Barker,et al. Development of an Ischemic Tolerance Model in a PC12 Cell Line , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[48] J. Sikorski,et al. Recent advances in therapeutic chalcones , 2004 .
[49] Grégori Gerebtzoff,et al. Halogenation of Drugs Enhances Membrane Binding and Permeation , 2004, Chembiochem : a European journal of chemical biology.
[50] M. Kikuchi,et al. Anti-allergic Activity of Naringenin Chalcone from a Tomato Skin Extract , 2004, Bioscience, biotechnology, and biochemistry.
[51] A. D'Ursi,et al. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. , 2002, European journal of biochemistry.
[52] J. Swatton,et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.
[53] K. Beyreuther,et al. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. , 1995, European journal of biochemistry.
[54] Manuela G. López,et al. Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds , 2017, Pflügers Archiv - European Journal of Physiology.
[55] D. Perl. Neuropathology of Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.
[56] C. Harrington,et al. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer’s disease , 1996, Acta Neuropathologica.
[57] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.